Agenix antibody in US diagnostic test
Thursday, 17 February, 2005
AGEN Biomedical, a subsidiary of Brisbane-based biotech Agenix (ASX: AGX), is set to receive royalties from a newly launched test developed by US diagnostics company Biosite that uses AGEN's D-Dimer antibody.
Biosite's Triage D-Dimer diagnostic is a point-of-care diagnostic for the assessment and evaluation of patients suspected of having thromboembolic events including pulmonary embolism and deep vein thrombosis. The ELISA-based test measures five biomarkers including D-Dimer, and provides results within 15 minutes. AGEN licensed the D-Dimer antibody and associated IP to Biosite in November 2003.
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
